UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000003673
Receipt number R000004352
Scientific Title FOLFOX plus bevacizumab alternated with sLV5FU2 plus bevacizumab as first-line chemotherapy for patients with metastatic colorectal cancer: a feasibility study
Date of disclosure of the study information 2010/05/31
Last modified on 2015/05/10 16:34:16

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

FOLFOX plus bevacizumab alternated with sLV5FU2 plus bevacizumab as first-line chemotherapy for patients with metastatic colorectal cancer: a feasibility study

Acronym

FOLFOX and bevacizumab alternated with sLV5FU2 and bevacizumab for patients with metastatic colorectal cancer

Scientific Title

FOLFOX plus bevacizumab alternated with sLV5FU2 plus bevacizumab as first-line chemotherapy for patients with metastatic colorectal cancer: a feasibility study

Scientific Title:Acronym

FOLFOX and bevacizumab alternated with sLV5FU2 and bevacizumab for patients with metastatic colorectal cancer

Region

Japan


Condition

Condition

Colorectal cancer

Classification by specialty

Gastroenterology Hematology and clinical oncology Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy and safety of an alternating regimen of FOLFOX plus bevacizumab with sLV5FU2 plus bevacizumab for patients with metastatic colorectal cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Response rate
Safety

Key secondary outcomes

Progression-free survival
Overall survival
Time to treatment failure


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Treatment consisted of modified mFOLFOX6 plus bevacizumab alternated biweekly with 5-FU/LV (simplified LV5FU2) plus bevacizumab. Treatment was administered until tumor progression, unacceptable toxicity or patient refusal.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Histologically confirmed adenocarcinoma of the colon and rectum
2. Unresectable or recurrent colorectal cancer
3. No prior chemotherapy
4. Previous adjuvant therapy of fluoropyrimidines is permitted if completed at least 6 months before registration.
5. ECOG performance status of 0,1
6. Life expectancy of longer than 3 months
7. Adequate organ function
8. Written informed consent

Key exclusion criteria

1. Brain metastasis
2. Massive pleural effusion or ascites
3. Active other malignancies
4. Nonhealing wound
5. Surgical procedure within 28 days before registration
6. Severe complications(bowel obstruction, symptomatic cardiovascular disease, interstitial pneumonitis, pulmonary fibrosis, uncontrollable hepertension, uncontrollable diabetes mellitus, active peptic ulcer, bleeding diathesis)
7. History of thromboembolitic disease
8. Uncontrollable diarrhea
9. Administration of corticosteroids
10. Administration of anticoagulants
11. Peripheral neuropathy
12. Active infectious disease
13. History of severe drug hypersensitivity
14. Psychosis
15. Pregnant or breast-feeding women
16. Men of wishing fertility
17. Not appropriate for the study at the physician's assessmnt

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Ayumu Hosokawa

Organization

University of Toyama

Division name

Department of Gastroenterology and Hematology, Faculty of Medicine

Zip code


Address

2630 Sugitani, Toyama, 930-0194, Japan

TEL

076-434-7301

Email

ayhosoka@med.u-toyama.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Ayumu Hosokawa

Organization

University of Toyama

Division name

Department of Gastroenterology and Hematology, Faculty of Medicine

Zip code


Address

2630 Sugitani, Toyama, 930-0194, Japan

TEL

076-434-7301

Homepage URL


Email

ayhosoka@med.u-toyama.ac.jp


Sponsor or person

Institute

University of Toyama

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2010 Year 05 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2009 Year 10 Month 19 Day

Date of IRB


Anticipated trial start date

2010 Year 04 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 05 Month 29 Day

Last modified on

2015 Year 05 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004352


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name